In 2023, Sihuan Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Sihuan Pharmaceutical has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2023 | 2022 | 2021 | 2020-2019 |
|---|---|---|---|---|
Total Scope 1 | 45,601.81a | 52,191.66a | 49,323.75b | |
Total Scope 2 | ||||
Unspecified Calculation Method | 58,465.86a | 71,100.59a | 73,499.96b | |
Total Scope 3 | N/A | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 174.1926a | 166.6136a | 103.4415b |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2023, the total operational greenhouse gas (GHG) emissions of Sihuan Pharmaceutical amounted to 104,067.67 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Sihuan Pharmaceutical decreased by 15.59%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2023, the total Scope 1 emissions of Sihuan Pharmaceutical were 45,601.81 metric tons of CO₂ equivalent (tCO₂e).a
Since 2021, Sihuan Pharmaceutical's Scope 1 emissions have decreased by 7.55%, reflecting a declining long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2022), Sihuan Pharmaceutical's Scope 1 emissions decreased by 12.63%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2023, Sihuan Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 58,465.86 tCO₂e without specifying the calculation method.a
Since 2021, Sihuan Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have decreased by 20.45%, reflecting a declining long-term trend in Scope 2 emissions over time.ab
Compared to the previous year (2022), Sihuan Pharmaceutical's Scope 2 emissions (Unspecified Calculation Method) fell by 17.77% in 2023, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.a
In 2023, Sihuan Pharmaceutical reported its Scope 2 emissions using an unspecified methodology.a
In 2023, Sihuan Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 45,601.81 tCO₂e and total revenues of USD 262 millions. This translates into an emissions intensity of 174.19 tCO₂e per millions USD.a
In 2023, Sihuan Pharmaceutical reported a Scope 1 emissions intensity of 174.19 tCO₂e per millions USD. Compared to the peer group median of 23.6, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2023, Sihuan Pharmaceutical ranked 25 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Sihuan Pharmaceutical among the least efficient performers, with one of the highest emissions intensities in its sector.a